Overview

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Adamis Pharmaceuticals Corporation
Treatments:
Tempol